The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3 billion.
ARCH Venture Partners led the pack, adding two funds totaling $1.46 billion to its war chest. Flagship... Read more »
Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible.
Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials... Read more »
Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs.
That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade”... Read more »
The coronavirus pandemic is narrowing the avenues open to biotechs for financing their endeavors, according to some industry veterans.
“I think that fear of losing out has pretty much gone out the window right now,” said Equillium (NASDAQ: EQ) CEO... Read more »
A type 2 diabetes drug marketed by Boehringer Ingelheim and Eli Lilly has fallen short of a bid to expand the medicine’s approval to patients who have type 1 diabetes.
The FDA on Friday rejected the application for the drug, empagliflozin... Read more »
The past week brought a sea change in many of our daily lives as the impact of the continued spread of the novel coronavirus altered how we work and play as communities around the world attempt to slow its spread.
Xconomy,... Read more »
The following sponsored content was submitted by commercial real estate brokerage firm Hughes Marino:
The story of the “canary in the coal mine” is an advanced warning of danger. The metaphor originates from when miners used to carry caged canaries... Read more »
The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but not in any way that people wanted or expected.
The World Health Organization this week... Read more »
Last month, Gilead Sciences CEO Daniel O’Day announced plans to introduce 10 “transformative medicines” over the next 10 years. Acquisitions would help meet that ambitious goal, and this week Gilead announced one of them: a nearly $5 billion deal for cancer... Read more »
The nomination period for the 2020 National Xconomy Awards is now open. The awards are open to individuals, companies, and organizations working across the life sciences in the United States, and feature leaders in the biotech industry, medicine, academia, digital health,... Read more »
Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. Making changes in the midst of the study was a no-no.
In recent years, regulators have showed openness... Read more »
[Updated 2/28/2020, 2:45 p.m. See below.] A Biohaven Pharmaceutical migraine drug has won FDA approval, clearing the way to the market for a new treatment option for the millions of people who suffer from the debilitating condition.
The... Read more »
A migraine drug that Lundbeck added to its pipeline via its nearly $2 billion acquisition of Alder BioPharmaceuticals won FDA approval on Friday.
The drug, eptinezumab (Vyepti), is part of a new class of antibody therapies developed to prevent migraine attacks... Read more »
The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by encouraging price competition.
The FDA has historically regarded insulin as... Read more »
Drugs typically go through three phases of clinical testing to support an application for FDA approval. It’s easy to overlook Phase 4, which takes place after a drug reaches the market.
Post-marketing studies aim to identify side effects not observed in... Read more »
Eisai is withdrawing weight-loss drug lorcaserin after a post-marketing study found a higher incidence of cancer in patients who took the medicine.
The FDA said Thursday that its request for removal of the product from the market is voluntary, but Eisai... Read more »
Pfizer and Merck are each cutting ties with a smaller clinical-stage biotech after experimental drugs being developed under separate alliances fell short in human testing.
Pfizer (NYSE: PFE) is walking away from a partnership with GlycoMimetics (NASDAQ: GLYC) a... Read more »
Two experimental drugs from Eli Lilly and Roche have failed a clinical trial testing them as treatments for a form of Alzheimer’s disease caused by certain genetic mutations, the companies reported Monday.
The study, sponsored by Washington University, tested the drugs... Read more »
The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics: price transparency and drug pricing reform.
President Trump asserted that an executive order he... Read more »
An Aimmune Therapeutics drug developed to treat peanut allergy won FDA approval late Friday—the first time the agency has approved an oral immunotherapy for a food allergy.
The Aimmune (NASDAQ: AIMT) drug, Palforzia, was developed to desensitize patients to peanuts... Read more »
If this week is any indication, the steady march of life science companies to Wall Street will continue in 2020. Black Diamond Therapeutics is leading the way, having raised $201 million from its IPO. In its first day of trading, the... Read more »
Some companies that belong to the Biotechnology Industry Organization (BIO), a large industry trade group, convene diverse hiring committees, seek out representation among their suppliers and vendors, and are led by executives that talk regularly about the importance of an inclusive... Read more »
Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems
